pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients

• US 7,670,627 B2
• Filed: 12/09/2002
• Issued: 03/02/2010
• Est. Priority Date: 12/09/2002
• Status: Expired due to Fees

• Current Assignee: Salvona LLC
• Original Assignee: Salvona IP LLC
• Inventors: Shefer, Adi, Shefer, Samuel David
• Primary Examiner(s): Silverman; Eric E.
• Application Number:
  US10/315,801
• Publication Number:
  US 20040109894A1
• Time in Patent Office: 2,640 Days
• Field of Search: None
• US Class Current: 424/502
• CPC Class Codes: A61K 49/0404 containing barium sulfate
• CPC Class Codes: A61K 49/0485 Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/5084 Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs tablets containing such a mixture A61K9/2077
• CPC Class Codes: A61K 9/5138 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention relates to a novel pH triggered, targeted controlled release system. The controlled delivery system of the present invention is substantially a free-flowing powder formed of solid hydrophobic nano-spheres comprising pharmaceutical active ingredients that are encapsulated in a pH sensitive micro-spheres. The invention also relates to the processes for preparing the compositions and processes for using same. The controlled release system can be used to target and control the release of pharmaceutical active ingredients onto certain regions of the gastrointestinal tract including the stomach and the small intestine. The invention further pertains to pharmaceutical products comprising the controlled release system of the present invention.

Claims

1. A multi-component controlled release composition comprising:

a plurality of solid nano-spheres encapsulated in a pH-sensitive or salt-sensitive micro-sphere, said pH-sensitive or salt-sensitive micro-sphere being formed of a pH-sensitive or salt-sensitive matrix material, and

a first pharmaceutical active agent incorporated by dispersion into a hydrophobic matrix forming the core of said plurality of solid nano-spheres or incorporated into both said hydrophobic matrix of said plurality of solid nano-spheres by dispersion and said matrix material of said micro-sphere, wherein said nano-spheres contact said matrix material of said microsphere, wherein said solid nano-spheres are formed of a wax material that has a melting point in the range of between about 25 degrees C. and about 150 degrees C. wherein said first pharmaceutical active agent is incorporated in said hydrophobic matrix of said solid nano-spheres and further comprising a second pharmaceutical active agent homogeneously incorporated in said pH-sensitive or salt-sensitive matrix material of said microsphere wherein said pH-sensitive or salt-sensitive matrix material of said microsphere releases said second active agent upon contact with a solution having a predetermined pH or predetermined salt concentration,

wherein said first pharmaceutical active agent and said second pharmaceutical active agent are not the same,

wherein said first pharmaceutical active is released continuously thereafter for an extended period of time,

and wherein said micro-sphere has a size of from about 20 to about 100 microns and each of said nano-spheres has an average size of about 0.01 to about 5 microns.

2. The composition according to claim 1 wherein said pH-sensitive micro-sphere degrades or dissolves when said pH-sensitive micro-sphere contacts a solution having a pH in the range of about 3 to about 12.

3. The composition according to claim 1 wherein said pH-sensitive or salt-sensitive matrix material degrades or dissolves when said pH-sensitive micro-sphere contacts a solution having a pH greater than about 5.

4. The composition according to claim 1 wherein said pH-sensitive or salt-sensitive matrix material is a cationic pH-sensitive polymer that is water insoluble at a pH above about 9 and is water soluble at a pH of about 7 or below.

5. The composition of claim 1 wherein said pH-sensitive material is selected from the group consisting of:

acrylate polymers with amino substituents, acrylic acid esters, polyacrylamides, phthalate derivatives and mixtures thereof.

6. The composition of claim 1 wherein said pH-sensitive material is selected from the group consisting of:

acid phthalate of carbohydrate, amylose acetate phthalate, cellulose acetate phthalate, cellulose ester phthalate, cellulose ether phthalate, hydroxy propyl cellulose phthalate, hydroxypropyl ethylcellulose phthalate, hydroxypropyl methyl cellulose phthalate, methyl cellulose phthalate, polyvinyl acetate phthalate, polyvinyl acetate hydrogen phthalate, sodium cellulose acetate phthalate, starch acid phthalate, styrene-maleic acid dibutyl phthalate copolymer, styrene-maleic acid polyvinyl acetate phthalate copolymer, styrene and maleic acid copolymer, gelatin, gluten, shellac, salol, keratin, keratin sandarac-tolu, ammoniated shellac, benzophenyl salicylate, cellulose acetate trimellitate, cellulose acetate blended with shellac, hydroxypropylmethyl cellulose acetate succinate, oxidized cellulose, polyacrylic acid derivative, acrylic acid and acrylic ester copolymers, methacrylic acid, methacrylic acid ester, vinyl acetate, crotonic acid copolymer and mixtures thereof.

7. The composition according to claim 1 wherein a first portion of said plurality of nano-spheres are adhered to a second portion of said plurality of nano-spheres with a pH-sensitive or salt-sensitive matrix material.

8. The composition according to claim 1 further comprising a moisture sensitive material mixed with said pH-sensitive or salt-sensitive material of said micro-sphere.

9. The composition according to claim 8 wherein said moisture sensitive material is selected from the group consisting of polyvinyl pyrrolidone, water soluble cellulose, polyvinyl alcohol, ethylene maleic anhydride copolymer, methyl vinyl ether maleic anhydride copolymer, polyethylene oxides, polyamide, polyester, copolymers or homopolymers of acrylic acid, polyacrylic acid, polystyrene acrylic acid copolymer, starch derivatives, polyvinyl alcohol, acrylic acid copolymer, anionic polymer of methacrylic acid and methacrylate, cationic polymer having dimethyl-aminoethyl ammonium functional groups, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose, carboxymethyl cellulose, hydroxypropyl carboxymethyl cellulose, hydroxypropyl methyl carboxyethyl cellulose, hydroxypropyl carboxypropyl cellulose, hydroxybutyl carboxymethyl cellulose, polysaccharide, hydrocolloid, natural gum, protein, and mixtures thereof.

10. The composition of claim 1 wherein said pH-sensitive material is relatively insoluble and impermeable at the pH of the stomach and is more soluble and permeable at the pH of the small intestine and colon.

11. The composition of claim 10 wherein said pH-sensitive material is selected from the group consisting of polyacrylamides, phthalate derivatives such as acid phthalates of carbohydrates, amylose acetate phthalate, cellulose acetate phthalate, other cellulose ester phthalates, cellulose ether phthalates, hydroxypropylcellulose phthalate, hydroxypropylethylcellulose phthalate, hydroxypropylmethylcellulose phthalate, methylcellulose phthalate, polyvinyl acetate phthalate, polyvinyl acetate hydrogen phthalate, sodium cellulose acetate phthalate, starch acid phthalate, styrene-maleic acid dibutyl phthalate copolymer, styrene-maleic acid polyvinylacetate phthalate copolymer, styrene and maleic acid copolymers, polyacrylic acid derivatives such as acrylic acid and acrylic ester copolymers, polymethacrylic acid and esters thereof, poly acrylic methacrylic acid copolymers, shellac, and vinyl acetate and crotonic acid copolymers.

12. The composition of claim 1 wherein said wax material has a penetration point of about 1 to about 10.

13. The composition of claim 1 wherein said wax material is selected from the group consisting of:

natural wax, synthetic wax, regenerated wax, vegetable wax, animal wax, mineral wax, petroleum wax, microcrystalline wax and mixtures thereof.

14. The composition of claim 1 wherein said wax comprises one or more of carnauba wax, candelilla wax and beeswax.

15. The composition of claim 1, wherein said micro-sphere further comprises a water sensitive material selected from the group consisting of:

natural oligomer, synthetic oligomer, natural polymer, synthetic polymer and copolymer, starch, starch derivative, oligosaccharide, polysaccharide, hydrocolloid, natural gum, protein, cellulose, cellulose derivative and mixtures thereof.

16. The composition of claim 1 further comprising a bioadhesive material incorporated into said solid nano-sphere or said micro-sphere or in both said nano-sphere and said micro-sphere.

17. The composition of claim 16 wherein said bioadhesive material is a bioadhesive polymer.

18. The composition of claim 17 wherein said bioadhesive polymer is selected from the group consisting of polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly (butyl methacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecylmethacrylate), poly(lauryl methacrylate), polyphenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) and poly(fumaric-co-sebacic)acid.

19. The composition of claim 1 wherein said nano-sphere further comprises a ligand.

20. The composition of claim 1 wherein said nano-sphere comprises a targeting material selected from the group comprising lectin, viral protein, bacterial protein, monoclonal antibody and antibody fragment.

21. The composition of claim 1 wherein said first pharmaceutical active agent is selected from the group consisting of:

analgesic, antihistamine, anti-emetic, anti-epileptic, vasodilator, anti-tussive agent, expectorant, anti-hypotensive, anti-inflammatory agent, anthelmintic, anti-arrhythmic agent, anti-bacterial agent, anti-viral agent, anti-coagulant, anti-depressant, anti-diabetic, anti-epileptic, anti-fungal agent, anti-gout agent, anti-hypertensive agent, anti-malarial, anti-migraine agent, anti-muscarinic agent, anti-neoplastic agent, anti-stroke agent, erectile dysfunction improvement agent, immunosuppressant, anti-protozoal agent, anti-thyroid agent, anxiolytic agent, sedative, hypnotic, neuroleptic, beta-Blocker, cardiac inotropic agent, corticosteroid, diuretic, anti-parkinsonian agent, gastro-intestinal agent, histamine receptor antagonist, keratolytic, lipid regulating agent, anti-anginal agent, cox-2-inhibitor, leukotriene inhibitor, macrolide, muscle relaxant, nutritional agent, opioid analgesic, protease inhibitor, sex hormone, muscle relaxant, anti-osteoporosis agent, anti-obesity agent, cognition enhancer, anti-urinary incontinence agent, nutritional oil, anti-benign prostate hypertrophy agent, essential fatty acid, non-essential fatty acid, antihemorrhoidal, psychotropic, antidiarrheal, mucolytic, decongestant, laxative, vitamin, stimulant, appetite suppressant, contraceptive, protein, peptide, sugar, natural agent and mixtures thereof.

22. The composition of claim 1 wherein said first pharmaceutical active agent is one or more of a drug or steroid.

23. The composition of claim 22 wherein said drug is selected from the group consisting of:

antibiotic, antiviral, antigen, vaccine, vasodilator, vasoconstrictor, immunomodulatory compound, cytokine, colony stimulating factor, tumor necrosis factor, interferon, oligonucleotide, nuclease, bronchodilator, hormone, calcitonin, insulin, erthropoietin, growth hormone and mixtures thereof.

24. The composition of claim 1 wherein said first pharmaceutical active agent is delivered to the colon.

25. The composition of claim 24 wherein said first pharmaceutical active agent is selected from the group consisting of:

nonsteroidal anti-inflammatory drug (NSAID), steroid drug, contraceptive, steroidal hormone, immunosuppressant, bronchodilator, anti-anginal, anti-hypertensive, anti-spasmodic agent, anti-colitis agent, anti-arrhythmia agent, anti-neoplastic agent, protein drug, peptide drug, interferon, calcitonin, leuprolide, tumor necrosis factor, bone growth factor, melanocyte-stimulating hormone, captopril, somatostatin, somatostatin octapeptide analog, cyclosporin, renin inhibitor, superoxide dismutase, vaccine, anticoagulant, anti-migraine drug, 5-hydroxytryptamine antagonistondansetron, menthol, antibiotic, beta-lactam, cephalosporin, macrolide, analogues for protecting the gastroduodenal mucosa from NSAID injury, and mixtures thereof.

26. The composition of claim 1 wherein said first pharmaceutical active agent is delivered to an alimentary canal.

27. The composition of claim 1 wherein said first pharmaceutical active agent is delivered to the stomach and/or small intestine.

28. The composition of claim 1 wherein said first pharmaceutical active agent is delivered to the gastrointestinal tract.

29. The composition of claim 1 wherein said first pharmaceutical active agent is an imaging agent.

30. The composition of claim 29 wherein said imaging agent is one or more of barium sulfate, siatrizoate sodium iodine containing contrast agents, ultra sound contrast agents, magnetic resonance imaging contrast agents, magnetic resonance imaging enhancements, tomography agents, and positron emission agents.

31. The composition of claim 1 wherein said pharmaceutical active agent is azithromycin and said pH-sensitive or salt-sensitive matrix composition is a pH dependent anionic polymer soluble at a pH above about 7.0 for delivering an azithromycin to the small intestine or colon.

32. The composition of claim 1 wherein said pharmaceutical active agent is pseudoephedrine and said pH-sensitive or salt-sensitive matrix composition is a pH dependent anionic polymer soluble at a pH above about 7.0 for delivering pseudoephedrine to the small intestine or colon.

33. The composition of claim 1 wherein said nano-spheres further comprise a cationic surface active agent, anionic surface active agent, a nonionic surface active agent or a zwitterionic surface active agent.

34. The composition according to claim 1 wherein the extended period of time is in the range of a day to a period of a few weeks.

35. The composition according to claim 1 wherein the makeup of said microsphere and said plurality of nano-spheres functions to provide that upon contact with said solution, said second pharmaceutical agent releases in a burst and said first pharmaceutical agent releases continuously thereafter for the extended period of time.

36. The composition according to claim 35 wherein the extended period of time is in the range of a day to a period of a few weeks.

39. An article formed of the composition of claim 1.

37. A pharmaceutical composition comprising a pharmaceutically and physiologically suitable carrier and a controlled release composition, the controlled release composition comprising:

a plurality of solid nano-spheres encapsulated in a pH-sensitive or salt-sensitive micro-sphere, said pH-sensitive or salt-sensitive micro-sphere being formed of a pH-sensitive or salt-sensitive matrix material, wherein said micro-sphere has a size of from about 20 to about 100 microns and each of said nano-spheres has an average size of about 0.01 to about 5 microns, wherein said solid nano-spheres are formed of a wax material that has a melting point in the range of between about 25 degrees C. and about 150 degrees C. and

a first pharmaceutical active agent incorporated into said plurality of solid nano-spheres or into both said microsphere or said nano-sphere, wherein said active agent is dispersed throughout a hydrophobic matrix of said solid nano-sphere or said matrix material of said micro sphere in a quantity sufficient for administration in a single or multiple dose regimen to a mammal, and wherein the hydrophobic nano-spheres contact said matrix material of said microsphere.

38. The pharmaceutical composition according to claim 37 formulated into a dosage form for administration, in which said dosage form is selected from the group consisting of powder, tablets, capsules and injectable compositions.

40. A method for delivering an active substance to a preselected environment;

said method comprising introducing to said environment a controlled release composition comprising;

a plurality of solid nano-spheres, said plurality of solid nano-spheres being encapsulated in a pH-sensitive or salt-sensitive microsphere, wherein said solid nano-spheres are formed of a wax material that has a melting point in the range of between about 25 degrees C. and about 150 degrees C. said pH-sensitive or salt-sensitive microsphere being formed of a pH-sensitive or salt-sensitive matrix material, and a first pharmaceutical active agent incorporated into a hydrophobic matrix of said plurality of solid nano-spheres or said microsphere or in both said hydrophobic matrix of said plurality of solid nano-spheres and said micro-sphere, wherein said active agent is dispersed throughout said solid nano-sphere or said matrix material of said microsphere, wherein said hydrophobic nano-spheres contact said pH-sensitive or salt-sensitive matrix material of said microsphere;

wherein said micro-sphere has a size of from about 20 to about 100 microns and each of said nano-spheres has an average size of about 0.01 to about 5 microns, and

wherein introducing said composition into said environment permits degradation of said composition and release of said active agent.

41. The method of claim 40 wherein said environment is the stomach or small intestine.

42. The method of claim 40 wherein said pH-sensitive micro-sphere degrades or dissolves when said pH-sensitive microsphere contacts a solution having a pH in the range of about 3 to about 12.

43. The method of claim 40 wherein said pH-sensitive material is selected from the group consisting of:

acid phthalate of carbohydrate, amylose acetate phthalate, cellulose acetate phthalate, cellulose ester phthalate, cellulose ether phthalate, hydroxy propyl cellulose phthalate, hydroxypropyl ethylcellulose phthalate, hydroxypropyl methyl cellulose phthalate, methyl cellulose phthalate, polyvinyl acetate phthalate, polyvinyl acetate hydrogen phthalate, sodium cellulose acetate phthalate, starch acid phthalate, styrene-maleic acid dibutyl phthalate copolymer, styrene-maleic acid polyvinyl acetate phthalate copolymer, styrene and maleic acid copolymer, gelatin, gluten, shellac, salol, keratin, keratin sandarac-tolu, ammoniated shellac, benzophenyl salicylate, cellulose acetate trimellitate, cellulose acetate blended with shellac, hydroxypropylmethyl cellulose acetate succinate, oxidized cellulose, polyacrylic acid derivative, acrylic acid and acrylic ester copolymers, methacrylic acid, methacrylic acid ester, vinyl acetate, crotonic acid copolymer and mixtures thereof.

44. The method of claim 40 wherein a first portion of said plurality of nano-spheres is adhered to a second portion of said plurality of nano-spheres by means of a pH-sensitive or salt-sensitive matrix material.

45. The method of claim 40 thither comprising a moisture sensitive material mixed with said pH-sensitive or salt-sensitive material of said micro-sphere.

46. The method of claim 40 wherein said active agent is selected from the group consisting of:

analgesic, antihistamine, anti-emetic, anti-epileptic, vasodilator, anti-tussive agent, expectorant, anti-hypotensive, anti-inflammatory agent, anthelmintic, anti-arrhythmic agent, anti-bacterial agent, anti-viral agent, anti-coagulant, anti-depressant, anti-diabetic, anti-epileptic, anti-fungal agent, anti-gout agent, anti-hypertensive agent, anti-malarial, anti-migraine agent, anti-muscarinic agent, anti-neoplastic agent, anti-stroke agent, erectile dysfunction improvement agent, immunosuppressant, anti-protozoal agent, anti-thyroid agent, anxiolytic agent, sedative, hypnotic, neuroleptic, beta-Blocker, cardiac inotropic agent, corticosteroid, diuretic, anti-parkinsonian agent, gastro-intestinal agent, histamine receptor antagonist, keratolytic, lipid regulating agent, anti-anginal agent, cox-2-inhibitor, leukotriene inhibitor, macrolide, muscle relaxant, nutritional agent, opioid analgesic, protease inhibitor, sex hormone, muscle relaxant, anti-osteoporosis agent, anti-obesity agent, cognition enhancer, anti-urinary incontinence agent, nutritional oil, anti-benign prostate hypertrophy agent, essential fatty acid, non-essential fatty acid, antihemorrhoidal, psychotropic, antidiarrheal, mucolytic, decongestant, laxative, vitamin, stimulant, appetite suppressant, contraceptive, protein, peptide, sugar, natural agent and mixtures thereof.

47. The method of claim 40 wherein said first pharmaceutical active agent is one or more of a pharmaceutical agent, cosmetic substance, drug or steroid.

48. The method of claim 40 wherein said active agent is selected from the group consisting of:

antibiotic, antiviral, antigen, vaccine, vasodilator, vasoconstrictor, immunomodulatory compound, cytokine, colony stimulating factor, tumor necrosis factor, interferon, oligonucleotide, nuclease, bronchodilator, hormone, calcitonin, insulin, erthropoietin, growth hormone and mixtures thereof.

49. The method of claim 40 wherein said environment is the colon.

50. The method of claim 40 wherein said environment is an alimentary canal.

51. The method of claim 40 wherein said environment is the gastrointestinal tract.

52. The method of claim 40 wherein said active agent is an imaging agent.

53. The method of claim 52, wherein said imaging agent is one or more of barium sulfate, siatrizoate sodium and iodine containing contrast agents.

54. The method of claim 40 further comprising a bioadhesive material incorporated into said plurality of solid nano-spheres or said micro-sphere or into both said plurality of solid nano-spheres and said micro-sphere.

55. The method of claim 40 wherein said bioadhesive material is a bioadhesive polymer.

56. The method of claim 40 wherein said nano-sphere further comprises a ligand.

57. The method of claim 40 wherein said nano-sphere comprises a targeting material selected from the group comprising lectin, viral protein, bacterial protein, monoclonal antibody and antibody fragment.

58. A controlled release composition comprising:

a first active agent;

a plurality of solid nano-spheres formed of a hydrophobic matrix at its core;

wherein said solid nano-spheres are formed of a wax material that has a melting point in the range of between about 25 degrees C. and about 150 degrees C. and

a micro-sphere formed of a pH-sensitive or salt-sensitive matrix;

wherein said first active agent is incorporated by dispersion in and dispersed throughout said hydrophobic matrix of said nano-spheres and said pH-sensitive or salt-sensitive matrix of said microsphere, wherein said first pharmaceutical active agent is incorporated in said hydrophobic matrix of said solid nano-spheres and further comprising a second pharmaceutical active agent homogeneously incorporated in said pH-sensitive or salt-sensitive matrix material of said micro sphere wherein said pH-sensitive or salt-sensitive matrix material of said microsphere releases said second active agent upon contact with a solution having a predetermined pH or predetermined salt concentration,

wherein said first pharmaceutical active agent and said second pharmaceutical active agent are not the same, and,

wherein said microsphere has a size of from about 20 to about 100 microns and each of said nano-spheres has an average size of about 0.01 to about 5 microns.